<?xml version="1.0" encoding="UTF-8"?>
<p>Currently, several new anti-herpetic drugs are being assessed in clinical trials, such as brincidofovir (
 <xref rid="B151" ref-type="bibr">Quenelle et al., 2010</xref>; 
 <xref rid="B149" ref-type="bibr">Prichard et al., 2011</xref>), amenamevir (
 <xref rid="B35" ref-type="bibr">Chono et al., 2010</xref>), pritelivir (
 <xref rid="B196" ref-type="bibr">Wald et al., 2014</xref>), and nelfinavir mesylate (
 <xref rid="B87" ref-type="bibr">Kalu et al., 2014</xref>).
</p>
